Subjects: RCL, CFG
Information Update - Update: Pfizer recalls Accupril blood pressure tablets due to a nitrosamine impurity
OTTAWA, ON, April 21, 2022 /CNW/ - Pfizer Canada ULC is recalling all lots of the prescription drug Accupril (quinapril hydrochloride) in 10 mg, 20 mg and 40 mg strengths due to the presence of a nitrosamine impurity (N-nitroso-quinapril) above the acceptable level.
Long-term exposure to N-nitroso-quinapril at a level above what is considered acceptable may increase the risk of cancer. This impurity is not expected to cause harm when ingested at or below the acceptable level. A person taking a drug that contains this impurity at or below the acceptable level every day for 70 years is not expected to have an increased risk of cancer.
Health Canada maintains a list of recalled quinapril drugs affected by this issue. Please see the full advisory for more information, including more on the risk and what patients should do.
Affected Products
Product | DIN | Lot | Expiry |
Accupril 10mg | 01947672 | DY3042 | 2023-03-31 |
Accupril 10mg | 01947672 | CK5285 | 2022-05-31 |
Accupril 20mg | 01947680 | DT9592 | 2023-03-31 |
Accupril 20mg | 01947680 | CK6258 | 2022-05-31 |
Accupril 20mg | 01947680 | CK6259 | 2022-05-31 |
Accupril 40mg | 01947699 | DT9591 | 2023-03-31 |
Accupril 40mg | 01947699 | CM2828 | 2022-05-31 |
Accupril 40mg | 01947699 | CM2829 | 2022-05-31 |
Également disponible en français
SOURCE Health Canada
These press releases may also interest you
|
News published on and distributed by:
